로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

AI Healthcare

SCL Healthcare Unveils ADC Drug Movement Analysis Technology

Dong-A Ilbo | Updated 2026.10.14
SCL Healthcare participates in international clinical trial conference ‘KIC’
SCL Healthcare presented its bioanalytical capabilities for new drug development, including antibody-drug conjugates (ADCs) and peptide therapeutics, at Asia’s largest international clinical trial conference. The company highlighted its strengths in pharmacokinetics, the field that analyzes how a drug is absorbed, distributed, metabolized, and excreted in the body during clinical trials.

SCL Healthcare announced on the 14th that it is participating in the ‘2026 KoNECT-MOHW-MFDS International Conference (KIC)’, held from the 13th to the 15th. KIC is co-hosted by the Ministry of Health and Welfare, the Ministry of Food and Drug Safety (MFDS), and the Korea National Enterprise for Clinical Trials (KoNECT). This year, approximately 1,500 experts from pharmaceutical and biotechnology companies, contract research organizations (CROs), and regulatory authorities are attending.

According to KoNECT, in 2024 Korea ranked sixth globally among countries in clinical trials, while Seoul ranked second among cities. The role of domestic clinical trial infrastructure and analytical capabilities in global new drug development is also expanding.

The theme of this year’s KIC is “Reshaping Life-cycle Strategies for Drug Development Amid a Fragmented Global Environment.” The event features sessions, exhibitions, and partnering programs covering topics such as clinical operations, advanced biopharmaceuticals, new technologies, and commercialization strategies.

SCL Healthcare showcased the pharmacokinetic analysis services of its Central Laboratory at its exhibition booth. Based on mass spectrometry items designated by the MFDS, the laboratory performs analyses of the in vivo kinetics of ADCs, analyses of peptide therapeutics, and anti-drug antibody (ADA) assessments. It also operates a system that integrates cold-chain transportation of clinical trial specimens with analysis, data processing, and data transfer.

Baek Se-yeon, Chief Operating Officer (COO) of SCL Healthcare, said, “In the rapidly changing regulatory environment of the global new drug development market, SCL Healthcare will strengthen its role as a partner to global pharmaceutical and biotech companies, backed by reliable data and technological capabilities.”

The SCL Healthcare Central Laboratory was established in 2006 and has conducted more than 800 clinical trial projects for new drug approvals to date. In 2019, it was designated as a clinical trial specimen analysis institution by the MFDS, and it has also obtained accreditation under ISO 15189, the international standard for medical laboratories.

Choi Hyun-jung

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!